Tradestie Institutional Equity Comparison Engine

AAPG vs BDCI โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BDCI Overall Edge

BDCI Captures Institutional Edge (2โ€“1 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to BDCI (BDCI) driven by superior Growth & Margin, Momentum & Technical while AAPG counters with relative strength in Valuation. Fundamentally, AAPG trades at 8.4x Forward P/E with -219.5% operating margin (+29.3% YoY revenue) versus BDCI at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, AAPG sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against BDCI sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner AAPG
AAPG 8.4x vs BDCI N/M Fwd P/E
Growth & Margin Winner BDCI
Op Margin -219.5% vs 0.0% ยท YoY +29.3% vs +0.0%
Momentum & Technical Winner BDCI
1Y -64.0% vs +0.3% ยท 52W Pos 0% vs 73%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
AAPG NASDAQ
Ascentage Pharma Group International American Depository Shares
Pharmaceutical Preparations
$11.97
-3.78% 1D
Market Cap $1.2B
1M Return -19.77%
1Y Return -64.0%
Forward P/E 8.4x
Unified AI Score
37.1 / 100 SELL
Tech 25.0 Fund 42.0 Flow 50.0 Mom 55.0
BDCI US Equity
BDCI
Institutional Equity
$10.18
+0.0% 1D
Market Cap $353.7M
1M Return +0.3%
1Y Return +0.3%
Forward P/E N/M
Unified AI Score
53.8 / 100 HOLD
Tech 43.0 Fund 50.0 Flow 50.0 Mom 46.2

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: AAPG -64.0% BDCI +0.3% Spread: +64.39 pp (BDCI Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
AAPG TTM Op. Margin: -219.5% BDCI TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AAPG vs BDCI. Trailing 12-month operating profitability (AAPG -219.5% vs BDCI 0.0%) and valuation multiples (AAPG 8.4x vs BDCI N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: AAPG (4) vs BDCI (6)
Institutional Metric AAPG BDCI Criterion Row Winner
Market Capitalization Scale $1.2B $353.7M Larger Scale AAPG
Trailing P/E Ratio Valuation 8.4x 46.3x Lower Multiple AAPG
Forward P/E Ratio Valuation 8.4x N/M Lower Multiple AAPG
Revenue Growth (YoY) Growth +29.3% +0.0% Higher Growth AAPG
Operating Margin (TTM) Profitability -219.5% 0.0% Higher Margin BDCI
Net Profit Margin Profitability -228.5% 0.0% Higher Margin BDCI
Return on Equity (ROE) Capital Efficiency -236.6% 6.0% Higher ROE BDCI
52-Week Range Position Momentum 0% ($12โ€“$34) 73% ($10โ€“$10) Stronger Trend BDCI
Beta / 30D Volatility Risk Regime 1.36ฮฒ ยท 64% Vol 0.00ฮฒ ยท 1% Vol Lower Realized Risk BDCI
Unified Institutional Score Composite Signal 37.1 / 100 (SELL) 53.8 / 100 (HOLD) Higher Composite BDCI

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full AAPG vs BDCI Buy Guide
AAPG UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live AAPG Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BDCI UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BDCI Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither AAPG nor BDCI registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.